|Bid||0.8500 x 480000|
|Ask||0.8750 x 480000|
|Day's Range||0.8350 - 0.8350|
|52 Week Range||0.6250 - 1.0500|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||14.40|
|Forward Dividend & Yield||0.02 (2.56%)|
|Ex-Dividend Date||Jun 06, 2022|
|1y Target Est||23.62|
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), today announced that it will report its Fourth Quarter & Full Year 2022 results on Wednesday, February 22, 2023 after the Mexican Market (BMV) close. The company also announced that it will hold a conference call on February 23, 2023 at 11 a.m. ET to discuss its quarterly financial results.
To increase access to high quality and affordable medicines in Latin America and the Caribbean Region ("LAC") and address the impact of the COVID-19 pandemic at a global scale, IFC is providing a US$60 million multi-currency long-term loan to Genomma Lab Internacional, S.A.B. de C.V. ("Genomma"), a leading pharmaceutical company based in Mexico.
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, will host its Investor Day and Site Visit ("Genomma Day") on Wednesday, March 8, 2023 in Mexico.